Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

hamburger
Point Nine Left Banner Point Nine Right Banner
Back All News & Events
News

ESMA updated EMIR Implementation Q&A (November 2021)

2021-11-22 06:11:03

The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, has updated Q&A on EMIR implementation

ESMA’s latest Q&A Update on EMIR Implementation is focused on two questions:

OTC Question 3 enriched with the additional clarification on ‘Calculation of the clearing threshold’ for financial counterparty that it should it include in the calculation the OTC derivative contracts that are objectively measurable as reducing risks directly relating to the commercial activity or treasury financing activity entered into by the non-financial counterparties that are part of the same group.

OTC Question 10 the European Commission in accordance with article 16b(5) of the ESMA Regulation clarified hedging exemption for non-financial counterparties when using OTC derivative contracts to hedge certain risks.

ESMA will periodically review and update Q & A’s. You can review previous Point Nine comments on ESMA updates here.


    Disclaimer: The content of this website is for general information purposes only. No other use of the content is permitted without the prior written consent of Point Nine. The content of the information found on our website is not comprehensive and does not constitute legal, financial, trading or regulatory advice. Although the information provided through the website is obtained through reliable sources, cannot substitute professional advice nor guarantee the accuracy, validity, timeliness or completeness of any information or data made available to you. Point Nine accepts no responsibility for any loss whatsoever and howsoever arising which might occur from reliance by any person on the content of this website.